Education, Science, Technology, Innovation and Life
Open Access
Sign In
  1. Home
  2. Journals
  3. MEDS Chinese Medicine
  4. Vol 7, Issue 4, 2025

Exploration on the Pathogenesis and Treatment of Microvascular Angina Pectoris Based on the Theory of "Xuqi Liuzhi"

Download as PDF

DOI: 10.23977/medcm.2025.070401 | Downloads: 3 | Views: 45

Author(s)

Dongyi Tao 1, Manting Zhang 1, Yuhua Xiang 1

Affiliation(s)

1 Heilongjiang Academy of Traditional Chinese Medicine, Harbin, Heilongjiang, 150000, China

Corresponding Author

Yuhua Xiang

ABSTRACT

Microvascular angina (MVA) is an ischemic chest pain syndrome caused by coronary microvascular dysfunction (CMD). It is a subtype of non-obstructive coronary artery disease (INOCA). Its clinical manifestations are highly consistent with the 'chest pain' of traditional Chinese medicine. Based on the theory of 'deficiency and qi stagnation', combined with the pathological correlation between this theory and MVA and the modern pharmacological mechanism, this paper discusses the pathogenesis and treatment of MVA. The key of this disease is deficiency in origin and excess in superficiality, 'deficiency qi' is the basis of pathogenesis, and deficiency of both heart and kidney is the basis; 'Retention' is the sign of the disease, with blood stasis, phlegm turbidity and other stagnation of heart collaterals as the sign. The treatment is based on the basic principle of 'tonifying deficiency and promoting stagnation'. The specific treatment method is to correct the deficiency of heart and kidney qi by replenishing qi and nourishing heart, tonifying kidney and consolidating root, etc., combined with the method of promoting blood circulation and removing blood stasis, removing phlegm and dredging collaterals to remove blood stasis and phlegm turbidity, so as to provide a new path for the diagnosis and treatment of MVA in traditional Chinese medicine.

KEYWORDS

Xuqi Liuzhi; Microvascular Angina; Pathogenesis; Treatment

CITE THIS PAPER

Dongyi Tao, Manting Zhang, Yuhua Xiang, Exploration on the Pathogenesis and Treatment of Microvascular Angina Pectoris Based on the Theory of "Xuqi Liuzhi". MEDS Chinese Medicine (2025) Vol. 7: 1-8. DOI: http://dx.doi.org/10.23977/medcm.2025.070401.

REFERENCES

[1] Cardiovascular Disease Branch of Chinese Medical Association. Chinese Expert Consensus on the Diagnosis and Treatment of Coronary Microvascular Disease (2023 Edition)[J]. Chinese Journal of Cardiology. 2024, 52(05):460-492. 
[2] Cardiovascular Disease Branch of Chinese Medical Association, Editorial Board of Chinese Journal of Cardiology. Expert Consensus of China on the Diagnosis and Management of Ischemia with Non-Obstructive Coronary Artery Disease[J]. Chinese Journal of Cardiology. 2022, 50(12):1148-1160. 
[3] China Cardiovascular Health and Disease Report 2024 Executive Summary[J]. Chinese Circulation Journal. 2025, 40(06):521-559. 
[4] Chebo, Yidong, Xu Chengyi, et al. Clinical research status of coronary microcirculation dysfunction in non-obstructive coronary artery ischemia[J]. Disease research. 2023, 21(01):89-94.
[5] Foa A, Canton L, Bodega F, et al. Myocardial infarction with nonobstructive coronary arteries: from pathophysiology to therapeutic strategies[J]. Journal of Cardiovascular Medicine, 2023, 24(Supplement 2): e134-e146.
[6] Han Mengyang, Li Hengda, Chen Yanan, et al. Research Progress of TCM Intervention in Microvascular Angina Pectoris[J]. Chinese Journal of Clinical Medicine. 2023, 35(11):2240-2245.
[7] Jin Yujing, Huang Shijing, Wang Yongyan. 'Deficiency and qi stagnation' pathogenesis theory research and play[J]. Chinese Journal of Traditional Chinese Medicine, 2024, 39(12):6310-6318. 
[8] Huang Shijing, Yin Yinghui. On 'virtual airflow stagnation'[J]. Journal of Beijing University of Chinese Medicine. 1996, (06):22-24.
[9] Sabe SA, Feng J, Sellke FW, et al. Mechanisms and clinical implications of endotheliumdependent vasomotor dysfunction in coronary microvasculature. Am J Physiol Heart Circ Physiol. 2022, 322(5):H819-H841. 
[10] Zhou Manli, Zhou Xiahui, Zhang Yifan, et al. To explore the formation mechanism of blood stasis syndrome of coronary heart disease based on the theory of 'heart governing blood vessels'[J]. Practical Journal of Cardio-cerebro-pulmonary Vascular Disease, 2023, 31(02):105-107. 
[11] Wu Yihang, Deng Cuiyun. Research progress on the pathogenesis and treatment of microvascular angina[J]. Chinese and foreign medical. 2017, 36(14):196-198. DOI:10. 16662/j. cnki. 1674-0742. 2017. 14. 196.
[12] Wang Jie, Hu Jun, Li Jun, et al. The theory and clinical practice of prevention and treatment of panvascular diseases under the core pathogenesis of 'kidney deficiency and pulse damage'[J]. Chinese Journal of Traditional Chinese Medicine. 2025, 50(13):3513-3521. 
[13] Law M, Wang PC, Zhou ZY, et al. From Microcirculation to Aging-Related Diseases:A Focus on Endothelial SIRT1. Pharmaceuticals (Basel). 2024, 17(11):1495. 
[14] Huang Ke, Zuo Keke, Gu Ning. To explore the scientific connotation of the pathogenesis of coronary microcirculation disorder 'deficiency qi stagnation' based on vascular endothelial function[J]. Liaoning traditional Chinese medicine Journal of Pharmaceutical University. 2025, 27(07):44-49. 
[15] Chen Yinying, Wang Jie. Professor WANG Jie's experience in treating coronary heart disease from kidney deficiency and blood stasis[J]. Emergency of traditional Chinese medicine in China, 2024, 33(09):1661-1664+1668. 
[16] Cai Yongyuan, Li Mengran, Hou Zhonghao, et al. To explore the pathogenesis and prevention strategies of microvascular angina pectoris from the theory of 'Qi-Blood-Vein'[J]. Combined traditional Chinese and Western medicine heart Journal of cerebrovascular disease. 2025, 23(03):459-465. 
[17] Li Hao, Yang Yingxi, Jia Qiujin, et al. Research progress on the pathogenesis and treatment of microvascular angina pectoris in traditional Chinese and Western medicine[J]. Liaoning Traditional Chinese Medicine Miscellaneous. 2020, 47(07): 196-200. 
[18] Wen W, Chi Y, Liu M, et al. Inflammation mediated glycolipid dysregulation in coronary microvascular diseas e pathogenesis. Sci Rep. 2025, 15(1):22694. 
[19] Fan M, Wang X, Peng X, et al. Prognostic value of plasma von Willebrand factor levels in major adverse cardiovascular events:a systematic review and meta-analysis[J]. BMC cardiovascular disorders, 2020, 20(1):72. 
[20] Pang Linlin, Zhang Huiyong, Min Dongyu, et al. Hyperlipidemia spleen deficiency phlegm turbidity pig serum high density lipoprotein to loss of functional high density lipoprotein transformation[J]. Journal of Traditional Chinese Medicine, 2022, 40 (09):78-82. 
[21] Fan Xiaodong, Zhao Yue. Correlation between influencing factors of prethrombotic state and platelet aggregation rate in patients with coronary heart disease[J]. China Health Engineering, 2020, 19(06):935-936. 
[22] Li Lijuan, Xu Wenhua, Yang Wenna, et al. To study the mechanism of ginseng in the treatment of coronary heart disease based on molecular docking and network pharmacology[J]. Liaoning Journal of Traditional Chinese Medicine, 2021, 48(03):7-11+222. 
[23] Yang Shan, Zhao Nuan, Yang Xin, et al. Research progress on the active ingredients and pharmacological effects of ginseng[J]. Traditional Chinese Medicine Bulletin, 2023, 29(01):105-+116. 
[24] Fu Huijie, Lei Genping, Dong Sheng, Wang Ting. Modern pharmacological effects and research progress of Astragalus mongholicus[J]. Hebei Traditional Chinese Medicine, 2025, 47(04):695-699+704. 
[25] Zhang Min, Liang Fengni, Sun Yanwen, et al. Research progress on chemical constituents, pharmacological effects and clinical application of eucommia ulmoides[J]. Chinese herbal medicine, 2023, 54(14):4740-4761. 
[26] Xu Peng, Yu Donghua, Zhou Qi, et al. Research progress on the correlation between the effect of Achyranthes bidentata and bone marrow mesenchymal stem cells[J]. Pharmacology and clinical application of traditional Chinese medicine Bed, 2024, 40(07):118-123. 
[27] Ying Feiyu, He Shiyan, Wang Xiaoxun. Research progress on the pharmacological effects of Morinda officinalis How[J]. Study on Zhuang and Yao medicine, 2023(01):296-298. 
[28] Xu Dongchuan, Yang Zongtong, Su Min. Research progress on modern pharmacological effects and mechanism of Polygoni Multiflori Radix[J]. Journal of Xi'an University of Arts and Sciences (Natural Science Edition), 2022, 25(02):79-83. 
[29] Wang Yuxin, Li Jinyang, Hu Tingting. Research progress on chemical constituents and pharmacological effects of Lycii Fructus[J]. Guangzhou Chemical Industry, 2024, 52(24):1-4. 
[30] Ma Lu, Yang Lei, Deng Changqing, et al. Research on the protective effect of endothelial progenitor cell-derived exosomes in combination with Danshenyuan IIA on oxidative damage of vascular endothelial cells based on the PI3K/Akt pathway[J]. Chinese Journal of Chinese Materia Medica, 2023, 48(23):6423-6433. 
[31] Huang Yidan, Cheng Jiaxin, Shi Ying, et al. Research progress on chemical constituents, chromatographic analysis, extract and pharmacological activity of Panax notoginseng in recent 5 years[J]. Journal of Materia Medica, 2022, 47 (10):2584-2596. 
[32] Yin Yue, Mou Chunyan, Shen Zixin, Zang Yingxin, Li Gaoqi. Research progress on chemical constituents and pharmacological effects of Chuanxiong Rhizoma[J]. Guanqiu Chinese Medicine, 2025, 18(03):635-641. 
[33] Bai Qirong, Guo Jiaojie, Wu Jiao. Research progress on chemical constituents and pharmacological effects of Flos Carthami[J]. Journal of Xinxiang Medical University, 2024, 41(01):88-94+100. 
[34] Zhai Chunmei, Meng Xiangying, Fu Jingju, Qin Zhen, Meng Yonghai. Research progress of modern pharmacy of Moutan Cortex[J]. Information of Traditional Chinese Medicine, 2020, 37(01):109-114. 
[35] Liu Hanbin, Liu Ruge, Wang Jiahui, et al. Research progress on modern clinical application and mechanism of action of Xuefu Zhuyu Decoction[J]. Chinese medicine guide Encore, 2024, 21(27):66-69+84. 
[36] Guo Rongxiang, Wang Kun, Li Yanli, et al. Research progress on the mechanism of action of active components in Trichosanthis Fructus[J]. Journal of Food Safety and Quality Inspection, 2023, 14(24):11-19. 
[37] Kang Yalong, Ning Bo, Tan Juanjuan, et al. Research Progress of Gualou Xiebai Banxia Decoction in the Treatment of Cardiovascular Diseases[J].Chinese Journal of Experimental Prescriptions, 2025, 31(02):256-267. 
[38] Chen J, Ye C, Yang Z, et al. Erchen decoction to reduce oxidative stress in dyslipidemia phlegm-dampness retention syndrome mice:In vivo mechanism revealed by metabolomics (liquid chromatography-mass spectrometry)[J]. Phytomedicine:international journal of phytotherapy and phytopharmacology, 2023, 115:154808.
[39] Wang Xianliang, Su Lishuo, Mao Jingyuan, et al. Effect of Liqi Huatan Huoxue Decoction on vascular endothelial function in rats with coronary microcirculation disorder[J]. Traditional Chinese medicine Magazine, 2019, 60(21):1849-1853+1860. 

Subscription
E-Mail Alert
Most popular papers
Call for Special Issue
Publication Ethics & OA Statement
Plagiarism Policy
Contact Us
Downloads: 9003
Visits: 587120

Sponsors, Associates, and Links

All published work is licensed under a Creative Commons Attribution 4.0 International License.

Copyright © 2016 - 2031 Clausius Scientific Press Inc. All Rights Reserved.